/images/ppid_59c68470-image-176068502895511690.webp)
What is the story about?
Shares of Natco Pharma Ltd. gained up to 3% on Friday, October 17, after the Supreme Court dismissed a plea by Roche, challenging the interim Delhi High Court Order on the roll out of the generic version of the Risdipalm.
The Supreme Court, during its hearing said that there is no reason to interfere with the interim order issued by the Delhi High Court and subsequently refused to restrain Natco Pharma from the sale and export of the generic version of the Risdipalm.
The Apex court has also directed that the hearing on the Roche-Natco dispute in the Delhi High Court should be expedited.
With this judgment, Natco Pharma can now sell the Spinal Muscular Atrophy treatment drug for ₹15,900 compared to the previous Roche's imported price of ₹6 lakh, resulting in a big win for patients. The drug from Roche and the generic version from Natco are packed in a 60 mg / 80 ml bottle.
The Risdipalm drug from Roche is used in the treatment of Spinal Muscular Atrophy. The company had moved the Supreme Court against the Delhi High Court order, which allowed Natco Pharma to sell the generic version of Risdipalm.
Shares of Natco Pharma are currently trading 1.6% higher at ₹834.85. However, the stock has been an underperformer in 2025, having declined as much as 40%.
The Supreme Court, during its hearing said that there is no reason to interfere with the interim order issued by the Delhi High Court and subsequently refused to restrain Natco Pharma from the sale and export of the generic version of the Risdipalm.
The Apex court has also directed that the hearing on the Roche-Natco dispute in the Delhi High Court should be expedited.
With this judgment, Natco Pharma can now sell the Spinal Muscular Atrophy treatment drug for ₹15,900 compared to the previous Roche's imported price of ₹6 lakh, resulting in a big win for patients. The drug from Roche and the generic version from Natco are packed in a 60 mg / 80 ml bottle.
The Risdipalm drug from Roche is used in the treatment of Spinal Muscular Atrophy. The company had moved the Supreme Court against the Delhi High Court order, which allowed Natco Pharma to sell the generic version of Risdipalm.
Shares of Natco Pharma are currently trading 1.6% higher at ₹834.85. However, the stock has been an underperformer in 2025, having declined as much as 40%.
Do you find this article useful?
